TL1A-related antibody compositions and methods of use

By developing TL1A-specific antibodies and antigen-binding fragments, the interaction between TL1A and DR3 was blocked, solving the treatment challenge of autoimmune diseases and achieving effective inhibition of the TL1A signaling pathway and therapeutic effects.

CN122122182APending Publication Date: 2026-05-29ABSCI CORPORATION
76 Cites 0 Cited by

Patent Information

Application Number
CN202480063410.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-08-13
Filing Date
2024-10-02
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Current technologies have failed to effectively target and inhibit the TL1A signaling pathway, resulting in the ineffective control of the development and pathogenesis of autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease.

Method used

The method provides a TL1A-specific antibody and an antigen-binding fragment, which competitively binds to TL1A, blocks the interaction between TL1A and DR3, and inhibits the TL1A signaling pathway. The preparation method includes identifying and modifying the CDR sequence to improve the affinity of the antibody for TL1A.

Benefits of technology

It effectively inhibits TL1A function, reduces cytokine release and inflammatory response, treats and prevents autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease, and enhances the binding affinity of antibodies to TL1A.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The disclosure herein relates to the development and production of novel antibodies and antigen-binding fragments thereof that bind to TL1A and are useful in the treatment, prevention and diagnosis of diseases, disorders or inflammations, including, for example, autoimmune diseases, such as, for example, autoimmune diseases, such as, for example, TL1A. Comprising rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease (Crohn's disease), psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis and fibrosis, including intestinal fibrosis, pulmonary fibrosis and hepatic fibrosis. Some of the elements of the final antibody structure are de novo designed by a computer system and its data training set without referencing a particular reference molecule.
Need to check novelty before this filing date? Find Prior Art